AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its earnings results on Wednesday. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16, Zacks reports. The firm had revenue of $72.00 million for the quarter, compared to analysts’ expectations of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. AngioDynamics updated its FY 2025 guidance to -0.340–0.310 EPS and its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Trading Up 12.4 %

NASDAQ ANGO opened at $10.86 on Thursday. The stock’s fifty day moving average price is $10.28 and its 200-day moving average price is $8.85. The stock has a market cap of $439.46 million, a P/E ratio of -1.93 and a beta of 0.56. AngioDynamics has a 12 month low of $5.47 and a 12 month high of $13.50.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is currently owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.